Trial
NCT01106950
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Leukemia, Myelogenous, Acute
Intervention
Natural Killer Cells
Why stopped
study drug (Ontak) no longer available
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-28